Extending beyond established cardiometabolic benefits of empagliflozin in type 2 diabetes: the evolving paradigm of glycemic variability

Dimitrios Patoulias; Emir Muzurović; Viviana Maggio; Manfredi Rizzo

doi:10.1016/j.jdiacomp.2026.109276

Extending beyond established cardiometabolic benefits of empagliflozin in type 2 diabetes: the evolving paradigm of glycemic variability

Dimitrios Patoulias
, Emir Muzurović
, Viviana Maggio
, Manfredi Rizzo

Mohammed Bin Rashid University Of Medicine and Health Sciences

Aristotle University of Thessaloniki
University of Montenegro
University of Palermo

Research output: Contribution to journal › Editorial

Original language	English
Article number	109276
Journal	Journal of Diabetes and its Complications
Volume	40
Issue number	4
DOIs	https://doi.org/10.1016/j.jdiacomp.2026.109276
State	Published - Apr 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Complication
Empagliflozin
Glycemic variability
Metformin
Type 2 diabetes

Access to Document

10.1016/j.jdiacomp.2026.109276

Cite this

@article{4cf703f8c87149bfb4d441b849a296d6,

title = "Extending beyond established cardiometabolic benefits of empagliflozin in type 2 diabetes: the evolving paradigm of glycemic variability",

keywords = "Complication, Empagliflozin, Glycemic variability, Metformin, Type 2 diabetes",

author = "Dimitrios Patoulias and Emir Muzurovi{\'c} and Viviana Maggio and Manfredi Rizzo",

year = "2026",

month = apr,

doi = "10.1016/j.jdiacomp.2026.109276",

language = "English",

volume = "40",

journal = "Journal of Diabetes and its Complications",

issn = "1056-8727",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Extending beyond established cardiometabolic benefits of empagliflozin in type 2 diabetes

T2 - the evolving paradigm of glycemic variability

AU - Patoulias, Dimitrios

AU - Muzurović, Emir

AU - Maggio, Viviana

AU - Rizzo, Manfredi

PY - 2026/4

Y1 - 2026/4

KW - Complication

KW - Empagliflozin

KW - Glycemic variability

KW - Metformin

KW - Type 2 diabetes

UR - https://www.scopus.com/pages/publications/105029411697

U2 - 10.1016/j.jdiacomp.2026.109276

DO - 10.1016/j.jdiacomp.2026.109276

M3 - Editorial

AN - SCOPUS:105029411697

SN - 1056-8727

VL - 40

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

IS - 4

M1 - 109276

ER -

Extending beyond established cardiometabolic benefits of empagliflozin in type 2 diabetes: the evolving paradigm of glycemic variability

UN SDGs

Keywords

Access to Document

Other files and links

Cite this